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Background: The antiretroviral treatment (ART) scale-up service has been a recent development in Ethiopia,
but its impact on mortality has not been well investigated. The aim of this study was to assess the early
survival outcome of the scale-up service by utilizing routine hospital data.
Methods: All adult HIV/AIDS patients who started on antiretroviral treatment in Shashemene and Assela
hospitals from January 1, 2006 to May 31, 2006 were included and followed up for 2 years. Data were
extracted from standard patient medical registrations. KaplanMeier curves were used to estimate survival
probability and the Cox proportional hazard model was applied to determine predictors of mortality. Two
alterative assumptions (real case and worst case) were made in determining predictors of mortality.
Results: The median age of patients was 33 years and 57% were female. Eighty-five percent had CD4B200
cells/mL with a median CD4 count of 103 cells/mL. The median survival time was 104.4 weeks. A total of 28
(10.3%) deaths were observed during the 2-year period and 48 patients (18%) were lost to follow up. The
majority of deaths occurred in the first 4 months of treatment. In multivariate analysis, 2-year survival was
significantly associated with the clinical stage of the disease, baseline hemoglobin, and cotrimoxazole
prophylaxis therapy (CPT) at or before ART initiation in both assumptions. The median CD4 count and
body weight showed a marked improvement during the first 6 months of treatment, followed by stagnation
thereafter.
Conclusion: The study has shown an overall low mortality but a high loss to follow-up rate of the cohort.
Advanced clinical stage, anemia, low body weight, and lack of CPT initiation were independent predictors of
mortality  but not gender. CPT initiation should be encouraged in routine HIV care services, and patient
retention mechanisms have to be strengthened. Stagnation in immunological and weight recovery after the
first 6 months should be further investigated. The utilization of routine data should be encouraged in order to
facilitate appropriate decision making.
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I
n 2008, an estimated 33.4 million people were living
with HIV/AIDS worldwide; nearly 70% of these were
found in sub-Saharan Africa (1). Due to a lack of
accessibility to treatment services, the sub-Saharan region
has also taken the largest share of the mortality burden
caused by the pandemic (2). However, the recent
extensive investments in expanding HIV/AIDS treatment
in low- and middle-income countries have resulted in a
marked improvement in antiretroviral treatment (ART)
coverage from 7% in 2003 to 42% in 2008 (3).
A few studies have been conducted to investigate the
survival benefit of ART scale-up services in Africa.
Though their findings showed a higher mortality com-
pared to high-income countries, the survival of the
patients improved and the incidence of opportunistic
infections (OIs) decreased (47). In these studies, the
degree of immunodeficiency was measured by clinical
or CD4 criteria; anemia, malnutrition, and bacterial
infections were all found to be important factors affecting
treatment outcome and subsequent survival (7).
In Ethiopia, 1,037,267 people were estimated to be
living with HIV in 2008. The antiretroviral scale-up
service has been expanding to all hospitals and most
health centers since 2005, and has achieved ART treat-
ment provision to a total of 175,612 patients (60.6%) out
of 289,734 who required it. A study done by Kloos et al.
in 2006 concluded that the sharp increase in national
ART utilization was the result of a combination of free
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indicated a national ART dropout rate of 20% (8).
The available evidence in the country regarding the
survival outcome in ART scale-up services is, however,
limited. Two previous studies, conducted in one district
hospital of Ethiopia before the national scale-up service
started, showed an improved survival and decreased
tuberculosis incidence in the early years of ART (9, 10).
But no study has focused on the survival outcome after
the ART scale-up service was initiated.
This study aimed to analyze the early survival outcome
of ART scale-up services and to identify predictors of
mortality in HIV-infected patients starting ART in two
hospitals from the Oromiyaa region, Ethiopia.
Methods
Setting
Ethiopia is a low-income country in east Africa, with a
total population of approximately 73 million according to
the 2007 demographic census. The 2005 Demographic
and Health Survey estimated the national adult HIV
prevalence to be 2.1% (11).
This study was conducted at two district hospitals,
Assela and Shashemene, located in the southern part of
the Oromiyaa region, Ethiopia. These are referral hospi-
tals in the Arsi zone with a catchment population of 2
and 1.5 million people, respectively. Both hospitals
provide general outpatient and inpatient services, includ-
ing surgical and obstetric emergency care. Infectious
diseases account for most of the inpatient and outpatient
visits. Both hospitals have been providing voluntary
counseling and testing (VCT) services for more than a
decade, and a free ART service was started in January
2006. The adult HIV prevalence rate of the region was
1.5% in 2008.
Patients who have tested positive for HIV at different
service outlets in the hospitals, or who have been referred
from elsewhere, are enrolled in HIV care. The clinical
services are provided by a multi-disciplinary ART team
(MDAT) comprising a doctor, a nurse, a pharmacy
technician, and a data clerk. Initial evaluation includes
clinical and CD4 staging, which determines whether ART
should be initiated. Treatment may also be initiated with
clinical parameters alone when the CD4 test is not
available. In addition to the medical eligibility, patient
adherence and commitment is mandatory. The medical
eligibility criteria for ART in the Ethiopian context is
presented in Table 1 (12).
Based on the 2007 ART guidelines of Ethiopia, the
preferred first-line regimen for adults and adolescents
comprises stavudine (d4T) or zidovudine (AZT), com-
bined with lamuvidine (3TC) and either efavirenez (EFV)
or nevirapine (NVP), depending on the patient’s clinical
condition (12).
Once the decision to initiate ART is made, the
appropriate regimen of highly active antiretroviral treat-
ment (HAART) will be started. Patients are advised to
return after 2 weeks to determine toxicity/tolerance or
adherence problems. The subsequent appointment sche-
dule depends on the condition of the patient, but usually
medication for 1 month will be dispensed and patients are
advised to have a review after day 28. After 3 months of
treatment, appointments are extended for patients with
better adherence to treatment and an improved clinical
condition. Cotrimoxazole prophylaxis therapy (CPT) is
also provided at the initial stage based on the guidelines.
During every visit, the patient’s counseling addresses
several issues including safe sexual practice, family
planning, adherence assessment, and support. A CD4
test is repeated every 6 months and patients showing
signs of treatment failure or poor clinical response are
referred to tertiary care for viral load tests and initiation
of a second line regimen. Liver enzyme tests are also
requested when necessary.
Patients who miss appointments are contacted by
telephone within days, but reaching those who do not
have a telephone remains a problem. Recently, a tracing
mechanism startedwith the involvement of peer educators
who often carry out planned home visits for patients lost
from care or treatment. Both laboratory tests and ART
drugs including CPTare provided free of charge as part of
the PEPFARand Global Fund for HIV, TB, and malaria.
Patient selection
A cohort of antiretroviral naı ¨ve
1 patients, who were
initiated on treatment between January 1, 2006 and
May 31, 2006, from the above two hospitals, were
Table 1. Eligibility criteria for ART in adults and adoles-
cents; adapted from the Ethiopian national ART guideline
CD4 count not available CD4 count available
WHO clinical stage IV and III
irrespective of total lymphocyte
count (TLC)
WHO clinical stage IV, irre-
spective of CD4 count
WHO clinical stage II if TLC
B1,200/mL
WHO clinical stage III, if CD4
cell counts 5350/mL
Do not treat WHO clinical stage I,
in absence of CD4 count
All WHO clinical stages, if
CD4 cell counts B200/mL
Note: TLC is only useful in deciding when to initiate ART in
symptomatic patients with WHO clinical stage II disease. The use
of CD4 cell count to guide treatment decision is advisable. For
example, pulmonary TB may occur at any CD4 level and other
conditions may be mimicked by non-HIV etiologies.
1ART Naı ¨ve: an individual who has never been on antiretroviral
therapy for the treatment of HIV infection.
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inclusion criteria were; (1) that they should be a
HIV-infected patient 15 years of age, and (2) that they
should have received ART on at least two clinical visits.
Patients starting treatment in other places, who had
previous ART history, were without baseline CD4 count
and lacking basic personal information, were excluded.
Data were extracted from the available standard
national medical registers, which have been adopted by
the Ministry of Health (MoH). The registers include the
Pre ART register (register of patients at their first visit),
the ART register (registration after ART initiation), and
the follow-up patient form; the latter is the form
completed for all patients at each visit, and on which
information regarding progressive weight change, clinical
stage, drug toxicity, adherence, newly diagnosed OI, and
laboratory test results is documented.
Statistical analysis
Epi-info 3.5.1 and STATA 10 were used for statistical
analysis. The main outcome variables were death and the
time of its occurrence during the 2-year period. The date
of censoring, including the lost-to follow-up date and
transferred-out date, was also used for survival time
calculations. The progressive 6-monthly CD4 and weight
changes were additional variables included in the analysis.
The survival time was calculated in weeks using the
time interval between the date of ART initiation and (1)
the date of event (death), (2) the date transferred out
(TO), (3) the date of the first missed appointment for
lost cases, and (4) the date on which the patient
completed the 24 months of follow up. The Kaplan
Meier model was used to estimate the survival prob-
ability after ART initiation, and p values were used to
compare survival curves. The Cox proportional hazard
model was used to assess the relationship between
baseline variables and mortality. The predictor variables
used in the analysis were age, sex, type of facility, WHO
clinical stage, baseline CD4 count, baseline body weight,
hemoglobin at cut-off point of 10 g/dL, and CPT
initiation. Variables that were statistically significant
(pB0.05) in the univariate analysis were subsequently
fitted into the multivariate analysis. Analyses of two
scenarios, a real-case assumption (confirmed dead cases
were used as events) and a worst-case assumption (lost
cases were also considered as events), were conducted
separately.
Ethical considerations
Permission was granted from Oromiyaa Regional Health
Office and hospitals. Data were kept confidential and
anonymous. Results of the study were summarized and
communicated to the authorities in the region.
Results
Baseline characteristics
A total of 290 patients were initiated with ART in both
facilities during the study period. Data available for
analysis included 272 ART patients (Fig. 1). The cohort
contributed to a total of 409.9 person-years of follow up.
The mean duration of follow up was 104.4 weeks.
The demographic characteristics of the cohort are
summarized in Table 2. Seven percent of patients were
under the age of 24, 47.4% were aged 2534, 28.7% were
aged 3544, and 16.9% were 45 or older at the time of
the treatment initiation. The median age of patients at
the start of the treatment was 33 years (range 1868).
The majority of the patients were women (57%). Sixty
percent of the patients started treatment in Assela
hospital. Nearly 82% of the patients had at least primary
school education or more. Forty-three percent of pa-
tients were married, 15.4% single, 22.4% divorced, and
18.4% were widows or widowers at the time of the
treatment initiation. Of the total, 59% of the patients
had a baseline weight less than 50 kg, although the
median baseline weight differed significantly between the
sexes: 46 kg (range 2491) for females and 52 kg (range
1479) for males (pB0.01).
The clinical parameters of the patients are summarized
in Table 3. Seventy-one percent of patients were staged
clinically as III/IV. By exclusive CD4 criteria, 85% of
patients had a CD4 count of B200 cells/mL, indicating
that the majority had advanced HIV disease at the
initiation of ART. The median CD4 count of the patients
at the time of the treatment initiation was 103 cells/mL
(range 1423). Eighty-two percent of the patients started
290 patients started on ART  
Assela: 175   Shashemene: 115 
10 aged < 15 yrs  
280 ART naïve
adults  
272 included for
analysis  
8 with incomplete
records: excluded  
Fig. 1. Inclusion of the study cohort for analysis.
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rest for clinical or combined reasons. Twenty percent had
one or more major OIs other than TB, and 23.3% had TB
a year before initiation of ART in both facilities. Nearly
40% of patients had a baseline hemoglobin level of B10
g/dL.
The regimen d4T3TCNVP was the most fre-
quently prescribed (36% of patients) followed by the
regimen d4T3TCEFV (28%). The initial ART regi-
men was changed for 32 (12%) of the patients during the
2-year follow-up period. The main reasons for regimen
change were ‘toxicity’ in 55% of the cases, followed by
‘new TB diagnoses’ in 29% of the cases for which NVP-
based regimens were switched to EFV-based regimens.
The AZT3TCNVP regimen was significantly more
associated with subsequent regimen change compared to
other regimens, for toxicity reasons (p0.029). The main
adverse effect was anemia due to AZT. CPTwas initiated
at or before ART initiation for 88.6% of the patients
(Table 3).
Survival analysis
A total of 28 (10.3%) patients were reported dead in the
2-year period after initiation of ART, and all of the
deaths except two occurred in the first year of follow up.
The median survival time for event (dead) cases was
13.4 weeks (range 1.7105), indicating that the majority
of the deaths occurred before the fourth month of
treatment. The rate of occurrence of death during the
follow-up period was 7/100 person-years. There was no
information available regarding the cause of death. The
remaining patients were censored for different reasons: 48
(18%) were lost to follow up, 19 (7%) TO to other
facilities, and 176 (64.7%) were alive at the end of the 24-
month follow-up period. The median baseline CD4 count
for lost to follow-up cases was 79 cells/mL, and was
significantly different from the survivors and TO groups,
Table 2. Socio-demographic characteristics of the study
participants
Characteristics
Number
(n272) Percentage
Total person years 410
Median duration of follow up (weeks) 104.4
Patients from hospitals
Assela 163 60.0
Shashemene 109 40.0
Median age (years) 33
Age in years
1524 19 7.0
2534 129 47.4
3544 78 28.7
 45 46 16.9
Sex
Women 155 57.0
Men 117 43.0
Marital status
Married 118 43.4
Never married 42 15.4
Divorced/separated 61 22.4
Widow/widower 51 18.4
Literacy status
Illiterate 51 18.8
Primary 124 45.6
]Secondary 97 35.7
Table 3. Clinical characteristics of the study participants on
initiation of ART
Characteristics
Number
(n272) Percentage
Baseline body weight (kg)
540 39 14.6
4050 120 44.8
5060 81 30.2
]60 28 10.4
WHO clinical stage
Stage I 25 9.1
Stage II 54 20.0
Stage III 147 54.0
Stage IV 46 16.9
TB history a year before initiation of ART
Present 63 23.2
Absent 209 76.8
Criteria for initiation of ART
Clinically only 10 3.7
CD4 B200 cells/mL 223 82.0
CD4 ]200 and stage III/IV 39 14.3
Original ART regimen
d4T3TCNVP 98 36.0
d4T3TCEFV 77 28.3
AZT3TCNVP 54 19.9
AZT3TCEFV 43 15.8
CPT initiation
Absent 31 11.4
Present 240 88.6
Hemoglobin (g/dL)
510 94 39.8
 10 142 60.2
CD4 count at baseline (cells/mL)
550 54 20.2
51200 173 64.8
 200 40 15.0
Regimen change
Absent 32 12.0
Present 240 88.0
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median follow-up time for lost cases was around 8.6
weeks.
The baseline variables clinical stage, hemoglobin, and
CPT initiation were associated with progression to death
in the univariate analysis using the real-case assumption,
but no association was found for gender, CD4 count,
literacy, marital status, type of ART regimen, and facility
of care. In the multivariable analysis, hemoglobin 510 g/
dL, clinical stage IV, and non-CPT initiation at or before
the start of the treatment, were significant predictors of
mortality (Table 4). The probability of 2 years’ survival
was significantly different for groups with a hemoglobin
level  10 g/dL compared to low hemoglobin groups, p
0.0079 (Fig. 2b). Similarly, the 2 years’ survival prob-
ability was significantly different between the groups with
and without CPT, p0.000 (Fig. 2a). A statistically
significant difference in survival probability was observed
among WHO clinical stages, ranging from 0.96 for
clinical stage I/II to 0.74 for stage IV, p0.012 (Fig. 2c).
In the worst-case assumption, advanced clinical stage,
hemoglobin510 g/dL, non-CPT initiation, and low
baseline body weight were associated with poor survival
in univariate analysis. All the above baseline variables,
except baseline body weight, were found to be signifi-
cantly associated with mortality in the multivariate
analysis (Table 5).
The indicators progressive CD4 change and weight
increment were used for measuring overall treatment
outcome. The median baseline CD4 count increased from
103 cells/mL at baseline to 242 cells/mL at 6 months, 265
cells/mL at 12 months, and 292 cells/mL at 24 months. The
median body weight increased by 4 kg at 6 months, but
showed no progressive improvement thereafter (Fig. 3).
Table 4. Hazard ratios of mortality according to baseline variables in HIV patients starting ART in Ethiopia (real-case
assumption)
Univariate analysis Multivariate analysis
Characteristics Hazard ratio (95% CI) p-Value Hazard ratio (95% CI) p-Value
Age (years)
1524 1.00 0.74
2534 0.78 (0.173.54) 0.73
3544 1.30 (0.295.93) 0.75
]45 1.30 (0.206.4)
Gender
Women 1.00 0.61
Men 1.22 (0.582.56)
Facility
Assela 1.00 0.60
Shashemene 1.22 (0.572.60)
Baseline weight (kg)
540 1.00 0.73
4050 1.24 (0.364.30) 0.81
5060 1.73 (0.324.32) 0.36
]60 0.35 (0.363.33)
WHO clinical stage
Stage I/II 1.00 1.00
Stage III 1.29 (0.493.40) 0.60 2.02 (0.974.20) 0.60
Stage IV 0.65 (1.3010.30) 0.01 5.13 (2.3311.33) 0.00
Hemoglobin (g/dL)
510 1.00 0.011 1.00 0.03
 10 0.35 (0.160.79) 0.39 (0.170.9)
CD4 count (cells/mL)
550 1.00 0.46
51200 0.59 (0.152.4) 0.72
]200 0.84 (0.332.13)
CPT initiation
Absent 1.00 0.00 1.00 0.00
Present 0.24 (0.110.54) 0.14 (0.050.37)
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This 2-year retrospective cohort study of HIV/AIDS
patients on ART gives an insight into survival and its
determinants in a hospital setting in Ethiopia. In this
cohort, 10.3% of the patients died, most of the deaths
occurring within the first 4 months. The overall mortality
rate was lower compared to other studies in Africa, in
which it was shown that in Tanzania and Cameroon,
29.7 and 23%, respectively, of the patients died during the
first 12 months of ART (5, 7). The high mortality in the
first few months of therapy was similar to other studies
from different African countries, including Ethiopia (4, 5,
7, 9, 13). The reason is probably that most of the patients
(85.5%) had advanced disease as evidenced by a baseline
of CD4B200 cells/mL. Prior lack of access to free ART
services, stigma related to HIV, and limited availability of
VCT services in most areas, might have played a role in
delaying diagnosis. Lack of proper screening of latent OI
and limited availability of prophylaxis and diagnostic
facilities for OIs may have also contributed to the early
mortality. The high mortality in the first few months
indicates the need to initiate ART early, which would
require early diagnosis of HIV. This could be addressed by
improving counseling and testing services at health
facilities, in addition to strong community education
and mobilization. The presence of advanced disease at
baseline in most cases requires closer attention and
frequent follow up by clinicians in order to prevent and
treat conditions in early phases.
The cause of death was not possible to investigate in
the current study. Studies from other African countries
have indicated TB, acute bacterial infection, flare up of
Table 5. Hazard ratios of mortality according to baseline variables in HIV patients starting ART in Ethiopia (worst-case
assumption)
Univariate analysis Multivariate analysis
Characteristics Hazard ratio (95% CI) p-Value Hazard ratio (95% CI) p-Value
Age (years)
1524 1.00 0.69
2534 1.22 (0.483.07) 0.79
3544 1.14 (0.433.02) 0.83
]45 1.12 (0.403.13)
Gender
Women 1.00 0.10
Men 1.44 (0.932.24)
Facility
Assela 1.00 0.13
Shashemene 0.70 (0.441.11)
Baseline weight (kg)
540 1.00 0.06 1.00
4050 0.58 (0.321.02) 0.02 0.91 (0.491.69) 0.75
5060 0.47 (0.250.89) 0.01 0.55 (0.241.22) 0.14
]60 0.25 (0.080.74) 0.26 (0.061.18) 0.08
WHO clinical stage
Stage I/II 1.00 0.04 1.00 0.25
Stage III 1.88 (1.013.5) 0.00 1.54 (0.733.25) 0.00
Stage IV 4.65 (2.389.12) 3.69 (1.608.47)
Hemoglobin (g/dL)
510 1.00 0.00 1.00 0.05
 10 0.48 (0.290.78) 0.64 (0.381.08)
CD4 count (cells/mL)
550 1.00 0.19
51200 0.70 (0.411.19) 0.47
]200 0.77 (0.371.58)
CPT initiation
Absent 1.00 0.03 1.00 0.00
Present 0.55 (0.310.97) 0.38 (0.190.73)
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main causes of death (1315).
The proportion of lost to follow up was 18%, which
was much higher than other studies from African settings
such as in Cameroon (5%) and Tanzania (9.7%) (5, 7).
The inverse relationship between overall low mortality
and high lost to follow-up rate found in our study has
also been observed in a systematic review of ART clinical
outcomes in 13 African cohorts by Rosen et al. in 2007
(16). Higher attrition is expected in programs of shorter
duration. Possible explanations include a lack of re-
sources and technical efficiency, which could affect
patient retention and the ability to monitor long-term
outcomes. In our context, where the majority of the
patients were in advanced clinical stage evidenced by a
median CD4 count of 79 cells/mL, most of the lost cases
were probably unrecorded deaths rather than living
patients. In handling this issue, a worst-case assumption
was also applied during the analysis.
In both assumptions, clinical stage at baseline, which is
an established predictor of survival in most studies, was
significantly associated with 2 years’ survival (10, 17, 18).
Hemoglobin510 g/dL at baseline was also strongly
associated with mortality in both assumptions. Several
previous studies revealed anemia as an independent
predictor of mortality in HIV patients (5, 17, 19). The
anemia could be explained as part of the advanced
clinical stage, especially secondary to latent OIs, but the
exact cause of anemia was impossible to determine. The
cause of anemia in HIV patients is likely to be multi-
factorial (factors such as bleeding, nutritional deficiency,
hemolytic anemia, bone marrow suppression, etc.). Con-
sidering the availability and affordability of hemoglobin
tests, anemia evaluation should be incorporated into the
routine care of HIV patients.
Similar to other studies, baseline CPT was strongly
related to survival in both assumptions, where patients
starting on CPT had a significantly lower risk of death
(20, 21). According to the national treatment guidelines,
CPT has to be started for all patients who are eligible
for ART, unless clinical contraindications exist. In our
study, several patients without contraindications were
not started on CPT  this might indicate a lack of
quality in the clinical care. Thus, the routine use of CPT
has to be strengthened in this setting (20, 21). There was
no significant difference in survival rates between the
sexes, unlike in other studies where men had a compar-
ably higher mortality than women (7, 22). In contrast to
many studies in which the CD4 count is an established
predictor of mortality, it was not found to be associated
with survival in our study. This may partly be explained
by the fact that the majority of patients (82%) had a
CD4B200 cells/mL, which could have made the com-
parison with higher CD4 counts statistically unstable
(23, 24).
The proportion of ART regimen change during the 2-
year period was comparable or even lower than that
observed in other cohorts (6, 25). This supports the view
that with proper and standardized clinical care, ART can
be safely used in resource-limited settings. The main
reason for regimen change was toxicity, followed by new
TB diagnosis. The NVP-containing regimen was switched
to an EFV-based regimen in TB patients, due to feared
pharmacological interaction of rifampicin and NVP.
Unlike findings in the developed world, regimen change
due to treatment failure was not observed in this
particular study. Similar findings were observed in one
hospital-based study from Arbaminch, Ethiopia, where a
regimen change due to drug side effects (but not due to
treatment failure) was observed (9, 25).
As the ART scaling-up service in Ethiopia was only
started a few years ago, treatment failure may not yet be a
common occurrence. The lack of availability of viral load
and ART drug resistance testing in the facilities might
have limited the capacity of diagnosing treatment failure,
even though clinical and immunologic clues of failure
(9 cases of TB and 22 cases of other OIs) were evident.
The progressive change in the weight and median CD4
count of the cohort was used as an indicator of treatment
outcome. The initial increase in the median value of both
measurements, pointing out an early immune recovery, is
(a)
0
20
40
60
80
100
baselinewe wt6month
wt12month wt18month
wt24month
(b)
0
500
1,000
1,500
2,000
2,500
cd4b cd46
cd412 cd424
Fig. 3. Quartiles of 6 months follow up for (a) body weight
and (b) CD4 count of patients.
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reasons for the subsequent stagnation, however, are not
clear, so long-term adherence problems should be taken
into consideration in future studies.
The short observation period of the cohort, together
with a high rate of censoring and lost to follow up with
untraced outcome, might have biased the study. Most of
the lost to follow-up cases had evidence of unfavorable
outcome (advanced clinical stage and low CD4 count), so
considering them as censored might have resulted in
differential misclassification, i.e. patients with advanced
disease and poor survival likelihood would be considered
as still being alive. To address this limitation, the worst-
case scenario assumption was made. The similar findings
in both assumptions strengthen our results. Other types
of bias may have resulted from the quality of the data, but
it was assumed to be non-differential.
Conclusion
The study has shown a high mortality of the cohort in the
first 4 months. An overall lower mortality, but higher lost
to follow-up rate, compared to other African studies, was
observed. Clinical stage IV, hemoglobin 510 g/dL, and
CPT initiation (but not gender) were strongly related to
mortality. The high early mortality has to be addressed
by increasing the availability of early HIV diagnosis and
treatment services, and by strengthening the quality of
existing ones. Proper nutritional assessment, including
anemia evaluation and treatment, has to be part of
routine care. The patient retention mechanisms must also
be strengthened to address the higher lost to follow-up
rate. The initiative of tracing lost cases through house
visits using peer educators requires special support and
monitoring. Stagnation in immunological and clinical
recovery after the first 6 months of treatment should be
investigated for possible treatment failure and drug
resistance.
Even though the current ART scale-up service has
included more than a hundred thousand patients, this
study could help as baseline data in showing the survival
experience of the earlier cohort. The utilization of routine
data should be encouraged in the Ethiopian setting for
the improvement of patient outcomes.
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